scholarly journals Correlation ER/PR status of Breast Carcinoma with Tumor size, Tumor grade, Lymphovascular emboli, Lymph node metastasis and the distant metastasis

2021 ◽  
Vol 6 (3) ◽  
pp. 191-196
Author(s):  
Vaibhav Mane ◽  
Nekta Anand ◽  
Darshana Wakkar
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Tumor Size ◽  
Tumor Grade ◽  
Tumor Type ◽  
Receptor Status ◽  
Node Metastasis ◽  
Poor Predictor ◽  
Size Grade

Breast cancer is the most frequent cancer in females in the world and is the second most common cancer in India after cervical cancer. The breast cancer is second most common reason of loss of existence in each developed and additionally most of the growing countries. For the appraisal of prognosis of breast cancer commonly followed is the NOTTINGHAM PROGNOSTIC INDEX (NPI) which includes- tumor size, histological tumor grade, lymph node metastasis and hormone receptor status. These prognostic component help in administration and therapeutic requirement of breast cancer patient.1. To study the MRM specimens for size, grade of the tumor, LVI and LN metastases and the ER/PR receptors of the tumor. 2.To study the association of ER/PR status with the above mentioned prognostic parameters.This three-year study includes 50 histopathologically confirmed cases of carcinoma breast. The tumor type, grade, LNM, LVE were reported on H & E. The ER-PR study was done of all 50 cases. The tumor size, grade, NM, LVE were correlated with receptor status. Out of 50 cases majority (7.5%) of cases were in 41-50 years of age group, and tumor size was between 2-4 cm in (17.5%) cases; majority were of grade II carcinoma (17.5%) of which 13% were ER-PR positive. Out of 35 cases with negative LNM and LVE, 26 cases (13%) were ER-PR positive.In our observation there is no association between higher histological grade and ER-PR status. No obvious correlation with tumor size was noted. But increase in tumor size could also be a poor predictor of ER-PR status. LNM, LVE is poor predictor of ER-PR status.

Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients

2008 ◽  
Vol 134 (11) ◽  
pp. 1229-1235 ◽  
Author(s):  
Sebastian Mayer ◽  
Axel zur Hausen ◽  
Dirk Otto Watermann ◽  
Stefan Stamm ◽  
Markus Jäger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Tumor Size ◽  
Breast Cancer Patients ◽  
Node Metastasis ◽  
Soluble Cd44

Correlation of quantitative total HER2 expression and HER2 homodimers with histopathologic characteristics of breast cancers in the FinHer study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 11061-11061
Author(s):  
W. Huang ◽  
J. Weidler ◽  
Y. Lie ◽  
J. Whitcomb ◽  
M. Leinonen ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Tumor Size ◽  
Dynamic Range ◽  
Tumor Grade ◽  
Her2 Status ◽  
Breast Cancers ◽  
Her2 Expression ◽  
Node Metastasis ◽  
Formalin Fixed Paraffin Embedded

11061 Background: We recently reported that the HERmark assay (Monogram Biosciences) accurately measures continua of total HER2 expression (H2T) and HER2 homodimers (H2D) over a wide (∼3 logs) dynamic range, and that a higher concordance was observed between H2T and HER2 status with more stringent central tests as compared with IHC tests performed locally (Joensuu et al, 2008 SABCS,abstract 2071). H2D/H2T ratio was reported as a marker of activated HER2 and a prognosticator of disease progression in HER2+ patients not treated with trastuzumab in the adjuvant setting (Bates et al, 2008 SABCS,abstract 1074). In this follow-up analysis, H2T, H2D, and H2D/H2T ratio were correlated with histopathologic characteristics of breast cancers in the FinHer study. Methods: The HERmark assay was used to measure H2T and H2D in 899 formalin-fixed, paraffin-embedded FinHer specimens. The results were correlated with histopathologic characteristics of breast cancers in the FinHer study (Joensuu et al, N Engl J Med2006;354), including estrogen receptor/progesterone receptor (ER/PR), tumor grade, tumor size, lymph node metastasis, and stage. Results: Higher H2T and H2D levels correlated with ER/PR negativity and high tumor grade (P<0.0001). 42% (102/244) of ER- and 37% (137/374) of PR- cases were HERmark Positive; while 17% (110/655) of ER+ and 14% (75/524) of PR+ cases were HERmark Positive. 10% (13/136) of grade 1, 18% (65/353) of grade 2, and 35% (131/375) of grade 3 tumors were HERmark Positive. No significant association was found between H2T or H2D and tumor size, lymph node metastasis or stage. ER/PR negative and poorly differentiated cancers had higher H2D/H2T ratios (P=0.013), and H2D/H2T ratios >0.6 were associated with smaller primary tumor diameters at the time of cancer detection (P=0.009). Conclusions: The quantitative H2T measurement confirms the known correlations between HER2 expression and histopathologic characteristics of breast cancer. The novel H2D measurement and H2D/H2T ratio may provide further insights into HER2 activation and better diagnostic tests for targeted HER2 therapy. [Table: see text]

Characteristics of medullary breast carcinoma compared with invasive ductal carcinoma.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 20-20
Author(s):  
Inhye Park ◽  
Jiyoung Kim ◽  
Se-Kyung Lee ◽  
Min-Young Choi ◽  
Su Yeon Bae ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Invasive Ductal Carcinoma ◽  
Tumor Size ◽  
Ductal Carcinoma ◽  
Histological Grade ◽  
Clinicopathologic Features ◽  
Node Metastasis

20 Background: Medullary carcinoma (MC) represents a rare breast cancer subtype associated with a rather favorable prognosis compared with invasive ductal carcinoma (IDC). It is characterized by the high-grade structure and lymphocytic infiltration, hemorrhagic necrosis. The purpose of this study is to compare the clinicopathologic characteristics and outcome of MC to IDC. Methods: We retrospectively reviewed the medical records of patients with invasive breast cancer managed with operation at Samsung Medical Center in Korea from January 1995 to June 2010 except patients diagnosed with ductal carcinoma in situ, patients with distant metastasis at diagnosis or neoadjuvant chemotherapy. 52 cases were identified with MC; 5,716 patients with IDC. The clinicopathologic features, disease-free survival (DFS) and overall survival (OS) for patients with MC were compared with those of the IDC patients. Results: The medullary group presented at younger age (43.9 ± 8.8 vs 47.7 ± 9.9, p=0.006). Also the medullary group was significantly associated with higher histological grade (poor; 80.0 vs 38.3%, p=0.003) and nuclear grade (grade3; 82.8 vs 41.7%, p<0.001) as well as negative ER (84.8 vs 31.0%, p<0.001) and PR status (91.3 vs 38.8%, p<0.001) regarded as poor prognostic factors. But lymphatic invasion was rare (0.0 vs 29.8%, p<0.001) and N stage was low (N0; 86.5 vs 58.4%, p<0.001). The DFS and OS were not significantly different between the medullary and IDC groups. (5-yr DFS : 88.0 vs 89.2 %, p=0.917, 5-yr OS : 94.4 vs 93.4%, p=0.502) In multivariable analysis, factors associated with DFS and OS included nuclear grade, histological grade, tumor size, lymph node metastasis, ER/PR/C-erbB2 status, chemotherapy and hormone therapy. When adjusting for other factors, histological type itself did not show significant difference from IDC in DFS and OS. Conclusions: Despite MC present specific clinicopathologic features, prognosis is not different from IDC and determined by already known prognostic factors such as tumor size, lymph node metastasis. Therefore, the patients with MC also need aggressive treatment like IDC.

scholarly journals Prognosis assessment of CD44+/CD24- in Breast Cancer Patients: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Jingjing Gu ◽  
Dandan Chen ◽  
Zhiqiang li ◽  
Yongliang Yang ◽  
Zhaoming Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Tumor Size ◽  
Meta Analysis ◽  
Breast Cancer Patients ◽  
Clinical Prognosis ◽  
Node Metastasis

Abstract Purpose: This meta-analysis investigated the relationships between the CD44+/CD24- phenotype and tumor size, lymph node metastasis, distant metastasis, disease-free survival (DFS), and overall survival (OS) in 8036 postoperative breast cancer patients enrolled in 23 studies.Methods: A literature search of PubMed, Medline, Cochrane, Embase, and PMC was conducted to identify eligible studies. The combined odds ratios (ORs) and 95% confidence intervals (95%CIs) were analyzed to evaluate the relationships between the CD44+/CD24- phenotype and the pathological and biological characteristics of breast cancer patients, and the combined hazard ratios (HRs) and 95% CIs were calculated to evaluate the relationships between CD44+/CD24- and DFS and OS of breast cancer petients using Stata12.0 software.Results: The CD44+/CD24- phenotype were not related to the tumor size (tumor size > 2.0 cm vs ≤ 2.0 cm, combined OR = 0.98, 95%CI: 0.68–1.34, p = 0.792) and didn’t promote lymph node metastasis (lymph node metastasis vs. no lymph node metastasis, combined OR = 0.94, 95% CI: 0.71–1.26, p = 0.692) and distant metastasis (distant metastasis vs no distant metastasis, combined OR = 3.88, 95% CI: 0.93–16.24, p = 0.064). The CD44+/CD24- phenotype was negatively correlated with postoperative DFS (HR = 1.67, 95% CI: 1.35–2.07, p <0.00001) and OS (combined HR = 1.52, 95%CI: 1.21–1.91, p = 0.0004).Conclusion: These results suggested expression of the CD44+/CD24- phenotype can be used as a reliable indicator of clinical prognosis and a potential therapeutic targets in breastcancer patients.

Doctor, What Are My Chances of Having a Positive Sentinel Node? A Validated Nomogram for Risk Estimation

2007 ◽  
Vol 25 (24) ◽  
pp. 3670-3679 ◽  
Author(s):  
José Luiz B. Bevilacqua ◽  
Michael W. Kattan ◽  
Jane V. Fey ◽  
Hiram S. Cody ◽  
Patrick I. Borgen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Logistic Regression ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Center ◽  
Tumor Type ◽  
Data Set ◽  
Specific Patient ◽  
Node Metastasis ◽  
Pathologic Features

Purpose Lymph node metastasis is a multifactorial event. Several variables have been described as predictors of lymph node metastasis in breast cancer. However, it is difficult to apply these data—usually expressed as odds ratios—to calculate the probability of sentinel lymph node (SLN) metastasis for a specific patient. We developed a user-friendly prediction model (nomogram) based on a large data set to assist in predicting the presence of SLN metastasis. Patients and Methods Clinical and pathologic features of 3,786 sequential SLN biopsy procedures were assessed with multivariable logistic regression to predict the presence of SLN metastasis in breast cancer. The model was subsequently applied to 1,545 sequential SLN biopsies. A nomogram was created from the logistic regression model. A computerized version of the nomogram was developed and is available on the Memorial Sloan-Kettering Cancer Center (New York, NY) Web site. Results Age, tumor size, tumor type, lymphovascular invasion, tumor location, multifocality, and estrogen and progesterone receptors were associated with SLN metastasis in multivariate analysis. The nomogram was accurate and discriminating, with an area under the receiver operating characteristic curve of 0.754 when applied to the validation group. Conclusion Newly diagnosed breast cancer patients are increasingly interested in information about their disease. This nomogram is a useful tool that helps physicians and patients to accurately predict the likelihood of SLN metastasis.

Sign in / Sign up

Export Citation Format

Share Document